Author

D. Alland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:database / resource· 1 Research Focus:genome assembly· 1 Organism:human· 1 Assay:metagenomics· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Levine· 3 shared P. Kumar· 3 shared H. Safi· 2 shared R. Shrestha· 2 shared V. Dartois· 2 shared A. D. Lemenze· 1 shared A. M. Eren· 1 shared A. R. Odom-Mabey· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. Levine

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Origin and dynamics of Mycobacterium tuberculosis subpopulations that predictably generate drug tolerance and resistance

D. Alland, J. Sebastian, A. Thomas, C. Levine, R. Shrestha, S. Levy, H. Safi, S. R. Pentakota, P. Kumar

This paper identifies drug-tolerant subpopulations in Mycobacterium tuberculosis using a multi-transwell system and barcoding, showing their role in generating resistance.

bioRxiv · Oct 5, 2022Microbiology

A comprehensive update to the Mycobacterium tuberculosis H37Rv reference genome

P. Chitale, A. D. Lemenze, E. C. Fogarty, A. Shah, C. A. Grady, A. R. Odom-Mabey, W. E. Johnson, J. H. Yang, A. M. Eren, R. Brosch, P. Kumar, D. Alland

The paper updates the M. tuberculosis H37Rv reference genome using Bact-Builder, revealing 6.4 kb of new sequence and ten new regions in widely used strains.

bioRxiv · Jul 15, 2022Microbiology

Development of amidase-dependent pyrazinoic acid prodrugs with activity against pyrazinamide resistant Mycobacterium tuberculosis

C. Levine, R. Jadhav, P. Yan, K. Tsotetsi, X. Wang, D. Awasthi, C. Grady, A. Shelke, S. S. Daher, T. Richmann, R. Shrestha, P. Sukheja, J. Patel, P. R. Barnett, R. J. Dikdan, , P. Kumar

This paper develops amidase-dependent pyrazinoic acid prodrugs that bypass PncA activation, showing efficacy against PZA-resistant Mtb.

bioRxiv · Jul 5, 2022 · PreprintMicrobiology

Xpert MTB/XDR: A ten-color reflex assay suitable for point of care settings to detect isoniazid-, fluoroquinolone-, and second line injectable drug-resistance directly from Mycobacterium tuberculosis positive sputum.

Y. Cao, H. Parmar, R. Gaur, S. Raghunath, D. Lieu, N. Via, S. Battagalia, D. M. Cirillo, C. Denkinger, S. B. Georghiou, R. Kwiatkowski, D. Persing, D. Alland, S. Chakravorty

The paper describes the development and evaluation of a 10-color Xpert MTB/XDR assay for rapid detection of drug resistance in tuberculosis directly from sputum samples.

bioRxiv · Sep 8, 2020Microbiology

Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance

H. Safi, P. Gopal, S. Lingaraju, S. Ma, C. Levine, V. Dartois, M. Yee, L. Li, L. Blanc, H.-P. H. Liang, S. Husain, M. Hoque, P. Soteropoulos, T. Rustad, D. Sherman, , D. Alland

This paper identifies a novel mechanism of drug tolerance in M. tuberculosis through phase variation in the glpK gene, showing reversible frameshift mutations that contribute to treatment failure and relapse.

bioRxiv · Jul 30, 2019Microbiology